ALLERGAN INC
DelistedCIK 850693fmd_08Y48RW6053K0ES37A0WYZF4NEManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2007 to Dec 31, 2014, 28 periods
| Line item | FY2007 | FY2008 | FY2009 | FY2010 | FY2011 | FY2012 | FY2013 | FY2014 |
|---|---|---|---|---|---|---|---|---|
| Total revenues | 3,939 | 4,403 | 4,504 | 4,919 | 5,216 | 5,647 | 6,300 | 7,238 |
| Realized investment gains (losses) | 0 | 0 | 25 | 0 | (1) | 0 | (4) | (3) |
| Research and development | 718 | 798 | 706 | 805 | 872 | 977 | 1,042 | 1,192 |
| Selling, general and administrative | 1,680 | 1,856 | 1,922 | 2,018 | 2,158 | 2,193 | 2,519 | 2,837 |
| Operating income | 719 | 796 | 928 | 259 | 1,375 | 1,611 | 1,809 | 2,009 |
| Interest expense | 95 | 86 | 77 | 79 | 72 | 64 | 75 | 69 |
| Interest and investment income | 65 | 34 | 7 | 7 | 7 | 7 | 7 | 8 |
| Other non-operating income (expense) | (55) | (34) | (80) | (88) | (65) | (80) | (79) | (20) |
| Income before taxes | 664 | 762 | 849 | 171 | 1,309 | 1,531 | 1,731 | 1,989 |
| Income tax expense | 177 | 198 | 225 | 166 | 360 | 430 | 458 | 457 |
| Net income from continuing operations | 487 | 565 | 624 | 5 | 950 | 1,101 | 1,273 | 1,533 |
| Net income | 485 | 563 | 621 | 1 | 935 | 1,099 | 985 | 1,524 |